Results 41 to 50 of about 276,897 (341)

Non-invasive assessment of murine PD-L1 levels in syngeneic tumor models by nuclear imaging with nanobody tracers [PDF]

, 2017
Blockade of the inhibitory PD-1/PD-L1 immune checkpoint axis is a promising cancer treatment. Nonetheless, a significant number of patients and malignancies do not respond to this therapy.
Breckpot, K, Broos, K, Devoogdt, N, Escors, D, Keyaerts, M, Lecocq, Q, Liston, A, Nguyen, T, Raes, G, Renmans, D   +9 more
core   +2 more sources

Programmed cell death ligand-1 (PD-L1) expression combined with CD8 tumor infiltrating lymphocytes density in non-small cell lung cancer patients

Journal of the Egyptian National Cancer Institute, 2018
Cancer immunotherapy targeting programmed cell death-1/programmed cell death ligand-1 (PD-1/PD-L1) pathway has shown promising results in treatment of non-small cell lung cancer (NSCLC) patients.
Dina M. El-Guindy, Duaa S. Helal, Nesreen M. Sabry, Mohamed Abo El-Nasr   +3 more
doaj   +1 more source

Myeloid-derived suppressor cells regulate the immunosuppressive functions of PD-1−PD-L1+ Bregs through PD-L1/PI3K/AKT/NF-κB axis in breast cancer

Cell Death and Disease, 2021
Myeloid-derived suppressor cells (MDSCs) are a heterogeneous group of myeloid cells that are closely related to tumor immune escape, but the mechanism by which MDSCs regulate B cells has not been elucidated.
Min Liu, Feng Wei, Jian Wang, Wenwen Yu, Meng Shen, Ting Liu, Dong Zhang, Yang Wang, Xiubao Ren, Qian Sun   +9 more
doaj   +1 more source

PD-L1 Expression in Lung Cancer [PDF]

Journal of Thoracic Oncology, 2016
Immunotherapies targeted against programmed death ligand 1 (PD-L1) and its receptor (PD-1) have improved survival in a subset of patients with advanced lung cancer. PD-L1 protein expression has emerged as a biomarker that predicts which patients are more likely to respond to immunotherapy. The understanding of PD-L1 as a biomarker is complicated by the
Hui, Yu, Theresa A, Boyle, Caicun, Zhou, David L, Rimm, Fred R, Hirsch   +4 more
openaire   +5 more sources

CTLA-4 and PD-1 ligand gene expression in epithelial thyroid cancers [PDF]

, 2018
The dysregulation of PD-1 ligands (PD-L1 and PD-L2) and CTLA-4 ligands (CD80 and CD86) represents a tumor strategy to escape the immune surveillance. Here, the expression of PD-L1, PD-L2, CD80 and CD86 was evaluated at mRNA level in 94 patients affected ...
Antonelli, Alessandro, Arcieri, Stefano, Baldini, Enke, Barollo, Susi, Carbotta, Giovanni, Catania, Antonio, Fallahi, Poupak, Mian, Caterina, Monti, Massimo, Palmieri, Andrea, Pironi, Daniele, Sorrenti, Salvatore, Tartaglia, Francesco, Tuccilli, Chiara, Ulisse, Salvatore, Vergine, Massimo   +15 more
core   +3 more sources

The predictive value of PD‐L1 expression in patients with advanced hepatocellular carcinoma treated with PD‐1/PD‐L1 inhibitors: A systematic review and meta‐analysis

Cancer Medicine, 2023
Background and Aim Programmed death 1 (PD‐1) and programmed death ligand 1 (PD‐L1) inhibitors have transformed the treatment landscape of advanced hepatocellular carcinoma (HCC), but consistent responses are not observed in all patients, and prognostic ...
Yao Yang, Dongbo Chen, Bigeng Zhao, Liying Ren, Rui Huang, Bo Feng, Hongsong Chen   +6 more
doaj   +1 more source

PD-L1 Distribution and Perspective for Cancer Immunotherapy—Blockade, Knockdown, or Inhibition

Frontiers in Immunology, 2019
Cancer immunotherapy involves blocking the interactions between the PD-1/PD-L1 immune checkpoints with antibodies. This has shown unprecedented positive outcomes in clinics.
Yilun Wu, Weiyu Chen, Zhi Ping Xu, Wenyi Gu   +3 more
doaj   +1 more source

Enhancing immunotherapy through PD‐L1 upregulation: the promising combination of anti‐PD‐L1 plus mTOR inhibitors

Molecular Oncology
Immune checkpoint inhibitors (ICIs) targeting the programmed cell death protein 1 (PD‐1)/programmed cell death 1 ligand 1 (PD‐L1) pathway have transformed urothelial cancer (UC) therapy.
Anna Hernández‐Prat, Alejo Rodriguez‐Vida, Laura Cardona, Mengjuan Qin, Oriol Arpí‐Llucià, Luis Soria‐Jiménez, Sílvia Menendez, Fabricio Gerel Quimis, Miguel Galindo, Edurne Arriola, Marta Salido, Nuria Juanpere‐Rodero, Federico Rojo, Aura Muntasell, Joan Albanell, Ana Rovira, Joaquim Bellmunt   +16 more
doaj   +1 more source

Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab

Scientific Reports, 2017
In 2016 and 2017, monoclonal antibodies targeting PD-L1, including atezolizumab, durvalumab, and avelumab, were approved by the FDA for the treatment of multiple advanced cancers. And many other anti-PD-L1 antibodies are under clinical trials.
Hyun Tae Lee, Ju Yeon Lee, Heejin Lim, Sang Hyung Lee, Yu Jeong Moon, Hyo Jeong Pyo, Seong Eon Ryu, Woori Shin, Yong-Seok Heo   +8 more
doaj   +1 more source

SUPREME-HN: a retrospective biomarker study assessing the prognostic value of PD-L1 expression in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. [PDF]

, 2019
BACKGROUND:Programmed cell death ligand-1 (PD-L1) expression on tumor cells (TCs) is associated with improved survival in patients with head and neck squamous cell carcinoma (HNSCC) treated with immunotherapy, although its role as a prognostic factor is ...
Baste, Neus, Clayburgh, Daniel, Cohen, Ezra EW, Fountzilas, George, Fujii, Takashi, Khaliq, Asud, Kim, Edward S, Lin, Derrick, Lipworth, Loren, Mehlhorn, Holger, Melillo, Giovanni, Pai, Sara I, Resteghini, Carlo, Shara, Nawar, Shire, Norah, Stokes, Michael, Twumasi-Ankrah, Philip, Wang, Huifen, Wildsmith, Sophie, Zhang, Jun   +19 more
core   +1 more source